RATIO-SALBUTAMOL HFA METERED-DOSE AEROSOL
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
03-01-2008
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
SALBUTAMOL (SALBUTAMOL SULFATE)
Inapatikana kutoka:
RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED
ATC kanuni:
R03AC02
INN (Jina la Kimataifa):
SALBUTAMOL
Kipimo:
100MCG
Dawa fomu:
METERED-DOSE AEROSOL
Tungo:
SALBUTAMOL (SALBUTAMOL SULFATE) 100MCG
Njia ya uendeshaji:
INHALATION
Vitengo katika mfuko:
200 DOSES
Dawa ya aina:
Prescription
Eneo la matibabu:
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0108887003; AHFS:
Idhini hali ya:
CANCELLED POST MARKET
Idhini ya tarehe:
2010-08-02
Tabia za bidhaa
_ _
_Product Monograph _
_Page 1 of 23_
PRODUCT MONOGRAPH
PR
RATIO-SALBUTAMOL HFA
salbutamol sulphate inhalation aerosol
(100 micrograms salbutamol/metered dose)
Bronchodilator
beta
2
-adrenergic stimulant
RATIOPHARM INC.
17 800 Lapointe
Mirabel, Quebec
Canada, J7J 1P3
Date of Preparation:
July 11, 2002
Date of Revision:
January 3, 2008
Submission Control No: 118739
_ _
_Product Monograph _
_Page 2 of 23_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................8
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND
STABILITY..........................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
PART II: SCIENTIFIC INFORMATION
...............................................................................17
PHARMACEUTICAL
INFORMATION..........................................................................17
DETAILED PHARMACOLOGY
..............................................................................
Soma hati kamili
